Serina Therapeutics (SER) Cash from Operations (2018 - 2025)

Serina Therapeutics has disclosed Cash from Operations across 8 years of filings, most recently posting -$6.1 million for Q4 2025.

• In Q4 2025, Cash from Operations fell 32.45% year-over-year to -$6.1 million; the TTM figure through Dec 2025 stood at -$18.0 million (down 5.04% YoY), while the FY2025 annual figure was -$18.0 million, down 5.04% from the prior year.
• Cash from Operations came in at -$6.1 million for Q4 2025 at Serina Therapeutics, down from -$3.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $121000.0 in Q4 2023 to a low of -$8.0 million in Q2 2024.
• Average Cash from Operations over 5 years is -$2.6 million, with a median of -$1.7 million recorded in 2021.
• Year-over-year, Cash from Operations soared 109.16% in 2023 and plunged 3892.56% in 2024.
• Over 5 years, Cash from Operations stood at -$1.6 million in 2021, then gained by 19.79% to -$1.3 million in 2022, then jumped by 109.16% to $121000.0 in 2023, then sank by 3892.56% to -$4.6 million in 2024, then slumped by 32.45% to -$6.1 million in 2025.
• Per Business Quant data, the three most recent Cash from Operations figures were -$6.1 million in Q4 2025, -$3.8 million in Q3 2025, and -$3.8 million in Q2 2025.